Next-generation sequencing technologies have recently been used in pharmacogenomic
studies to characterize large panels of cancer cell lines at the genomic and transcriptomic
levels. Among these technologies, RNA-sequencing enable profiling of alternatively spliced
transcripts. Given the high frequency of mRNA splicing in cancers, linking this feature to drug
response will open new avenues of research in biomarker discovery. To identify robust
transcriptomic biomarkers for drug response across studies, we develop a meta-analytical …